title: The effect of celecoxib on tissue factor expression in pancreatic cancer cells.
abstract: BACKGROUND
  Tissue factor (TF) is overexpressed in many malignant tumours and is linked to the pathogenesis and prognosis of such malignancies. In vitro studies have proved that reduced expression of TF has inhibitory effect on the angiogenesis and cell proliferation of the malignant tumour. Therefore, TF suppression has been raised as a possible treatment for malignant tumours. Here we investigated the effect of celecoxib on TF expression induced by tumour necrosis factor alpha (TNFalpha) in PANC-1 cells and a possible molecular mechanism underlying the celecoxib effect.
  
  
  METHODS
  Various doses of celecoxib solution were added to standard cell numbers of PANC-1 cells mixed with equal dose of TNFalpha for 6 hours. The expression of tissue factor was detected quantitatively by Western blot, whilst the activation of nuclear factor kappaB was tested by electromobility shift assay.
  
  
  RESULTS
  As the doses of celecoxib increased, the tissue factor expression was decreased in PANC-1 cells and so was the activation of nuclear factor kappaB.
  
  
  CONCLUSIONS
  Celecoxib can downregulate the expression of tissue factor induced by TNFalpha in PANC-1 cells. This antitumour effect of celecoxib can be explained indirectly via its suppressive role in activation of nuclear factor kappaB.
authors.affiliation: Department of General Surgery, Xuanwu Hospital of Capital Medical University, Beijing 100053, China.
authors.forename: Hui-yuan
authors.initials: HY
authors.lastname: Wang
authors.forename: Yin-mo
authors.initials: YM
authors.lastname: Yang
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhuang
authors.forename: Huan-nian
authors.initials: HN
authors.lastname: Chen
authors.forename: Yuan-lian
authors.initials: YL
authors.lastname: Wan
authors.forename: Yan-ting
authors.initials: YT
authors.lastname: Huang
mesh_terms: D000068579:Celecoxib; D045744:Cell Line, Tumor; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D016328:NF-kappa B / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D011720:Pyrazoles / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*; D013925:Thromboplastin / Q000235:genetics*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D016328:NF-kappa B; D011720:Pyrazoles; D013449:Sulfonamides; D014409:Tumor Necrosis Factor-alpha; D013925:Thromboplastin; D000068579:Celecoxib